In Florida, Dyadic has announced that it has launched Fibrezyme G4, a high performance cellulase enzyme product designed to enhance paper and textile quality. The enzyme has shown to reduce energy requirements and increase production rates for pulp and paper manufacturers. Dyadic Chief Operating Officer Danai Brooks commented: “We expect two key markets to be […]
In the Netherlands, Dyadic has received a US patent for its C-1 technology that is currently being implemented at Abengoa’s cellulosic ethanol plant that’s getting read to start up in Hugoton, Kan. As Abengoa goes to license its technology package, Dyadic’s C-1 would be the enzyme component. The patent is Dyadic’s 14th.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries. Rankings 50 Hottest Companies in Bioenergy: 2013/14, #46 The Situation In their 2013 results, […]
In Florida, Dyadic International has announced their financial results for the FY2013. Total revenue for the company increased 10% for the year compared to FY2012, with net product-related revenue increasing 25% to $9.8 million. The increase was driven primarily by increases in the animal health and nutrition segments, the addition of two major customers and […]
This is the official Transformative Technologies 2014 nominee page for Dyadic, nominated in the “Transformative Enzyme or organic catalyst” category for its C1 expression system. Voting Rules All voting is exclusively via social media this year. To vote, simply click on the Tweet, Like or Share link in on this page. Each tweet, like or share […]
In Florida, Dyadic International, Inc. announced that the expansion of its research laboratory in The Netherlands is now complete. Floor space at Dyadic Netherlands has significantly increased allowing for the installation of a wide range of state-of-the-art research equipment including a new fermentation lab. In addition, the expansion will facilitate the housing of new scientists […]
In Florida, Dyadic International reports that during the third quarter of 2013, the Company recognized a loss of $313,000 on settlement of litigation, while net income for the nine months was $121,000, compared to a net income of $2.8 million for the same period a year ago. Dyadic reports that for the 2013 full-year outlook, […]
In Florida, Dyadic (OTC Pink: DYAI) announced that it has been issued U.S. Patent No. 8,551,751 B2 entitled, “BX11 Enzymes Having Xylosidase Activity” by the United States Patent and Trademark Office (“USPTO”). The invention relates to methods of developing and producing novel enzymes, more specifically for the development of a variety of fungal enzymes. In addition, […]
In Florida, Dyadic International announced that it has entered into agreements with all of its outstanding promissory note holders to extend their maturity dates to January 1, 2015. The convertible portion of the debt, representing $6.8 million of the total $8.2 million outstanding principal, may be prepaid by Dyadic at any time in whole or […]
In California, Codexis announced that the company has received notice from Dyadic International, Inc. alleging that Codexis is in breach under a license agreement established by the companies on November 14, 2008. According to the notice, Dyadic intends to terminate the agreement in 60 days if the breach is not cured to Dyadic’s satisfaction. Codexis […]
